Sales & Marketing News | pharmaphorum

News

Takeda tries again with subcutaneous Entyvio

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerativ

News

AbbVie’s growth drugs fail to offset Humira competition

Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it

News

Changing Faces: Digital health and pharma supplier hires fro...

For our final March hires roundup instalment, we have our “pharma-adjacent” roundup which includes CROs, clinical trial software companies, manufacturing organisations, suppliers, non-profi

News

Lilly trumpets new weight-loss data with Mounjaro

Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.

News

Changing Faces: Agency, consultancy, and investor hires from...

In March we saw just a handful of hires in the pharma marketing world, including some high-profile appointments.

News

Boerner to lead BMS after CEO Caforio steps down

Bristol-Myers Squibb’s long-serving chief executive Giovanni Caforio has said he will retire on 1st November after almost eight years in the role and more than two decades

Takeda tries again with subcutaneous Entyvio

AbbVie’s growth drugs fail to offset Humira competition

Changing Faces: Digital health and pharma supplier hires fro...

Lilly trumpets new weight-loss data with Mounjaro

Changing Faces: Agency, consultancy, and investor hires from...

Boerner to lead BMS after CEO Caforio steps down

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks